Abstract
The closely-related primary granule proteins are a source of multiple antigens with immunotherapeutic potential for myeloid leukemias. To further explore the possibility of generating leukemia-specific T cell responses, DNA vectors encoding the primary granule proteins proteinase 3 (PR3), human neutrophil elastase (HNE) and cathepsin-G (CathG) were transfected into autologous CD40-activated B (CD40-B) cells and used to stimulate T cell responses from peripheral blood T cells of five patients with myeloid malignancies and three ALL patients three months post-bone marrow transplantation (BMT), and one patient with CML-BC pre-transplant. T-cell responses were measured by flow-based intra-cytoplasmic IFN-g assay and cytotoxic assay. CD8 and CD4 cell response to PR3 and HNE were observed in CD8+ and CD4+ T-cells in 6/6 patients with myeloid leukemias with various degrees. T-cell response against CathG were found in both myeloid and lymphoid leukemias. We conclude that gene-transfected CD40-activated B cells are fully capable of expanding functionally-competent primary granule protein-specific CD4 and CD8 T cells, making this approach a valuable means of expanding leukemia antigen-specific T cells for adoptive immunotherapy.
PGP-DNA primed T cells showed CTL activity to CML cell (case#5, post transplant)
. | . | CTL activity % . | ( E:T ratio ) . | . |
---|---|---|---|---|
CML cell; recipient BM cell, normal BM; HLA identical DNR BM cells | ||||
Effector cells | Target | 50:1 | 25:1 | 12.5:1 |
PR3-primed | CML cell | 63.8 | 54.6 | 30.4 |
normal BM | 15.5 | 13.1 | 5.9 | |
HNE-primed | CML cell | 43.9 | 38.3 | 32.1 |
normal BM | 0 | 4.1 | 2.3 | |
CathG-primed | CML cell | 43.1 | 29.1 | 27.5 |
normal BM | 0 | 0 | 1.7 | |
mock-primed | CML cell | 33.3 | 34.2 | 29.5 |
normal BM | 5.5 | 12.9 | 0 |
. | . | CTL activity % . | ( E:T ratio ) . | . |
---|---|---|---|---|
CML cell; recipient BM cell, normal BM; HLA identical DNR BM cells | ||||
Effector cells | Target | 50:1 | 25:1 | 12.5:1 |
PR3-primed | CML cell | 63.8 | 54.6 | 30.4 |
normal BM | 15.5 | 13.1 | 5.9 | |
HNE-primed | CML cell | 43.9 | 38.3 | 32.1 |
normal BM | 0 | 4.1 | 2.3 | |
CathG-primed | CML cell | 43.1 | 29.1 | 27.5 |
normal BM | 0 | 0 | 1.7 | |
mock-primed | CML cell | 33.3 | 34.2 | 29.5 |
normal BM | 5.5 | 12.9 | 0 |
Author notes
Corresponding author